Compare Alliant Energy Corporation (LNT) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alliant Energy Corporation vs Vertex Pharmaceuticals Incorporated — how do they compare? Alliant Energy Corporation trades at $65.85 (market cap $16.99B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 7.5× Alliant Energy Corporation's market cap, and Alliant Energy Corporation pays a 3.27% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alliant Energy Corporation for 64 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| LNT | VRTX | |
|---|---|---|
Market Cap | $16.99B | $127.55B |
Volume | 2,488,387 | 1,487,944 |
Sector | Utilities | Health |
52-Week High | $78.03 | $557.96 |
52-Week Low | $63.21 | $407.37 |
Typical Hold Time | 64 Days | 120 Days |
Enterprise Value | $29.08B | $121.68B |
Dividend Yield | 3.27% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LNT trades at $65.85, up 0.98% today, with a bullish technical signal and strong earnings beats in recent quarters. The company reported 2025 revenue of $4.36B and net income of $810M, with a net margin of 18.56%. A $13.4B capital investment plan supports long-term growth, while analyst consensus is a Buy with a $77.00 price target, implying significant upside from current levels.
Outlook remains positive due to steady utility demand and data center growth, but risks include rising debt levels and cost pressures. The stock offers a defensive profile with a 23-year dividend growth history, though valuation multiples like a P/E of 20.74 require sustained earnings expansion to justify further gains.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, amid a bearish technical signal but strong fundamentals. The company reported $12.0B revenue and $4.0B net income for 2025, with robust profitability margins. Recent positive Phase 2b trial results for its kidney disease drug inaxaplin highlight pipeline progress. Support and resistance levels are tightly clustered around the current price, indicating potential for near-term volatility.
Outlook remains positive given dominant cystic fibrosis franchise, high margins, and promising pipeline, though earnings misses and competitive pressures pose risks. Analyst consensus is strongly bullish with a $573.50 price target, suggesting ~14% upside. Key risks include clinical trial outcomes and reliance on core franchise growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
